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Abstract Eldecalcitol, a vitamin D3 analogue, signifi-
cantly reduces the risk of new vertebral fractures and
increases bone mineral density (BMD) more than does
alfacalcidol. To determine the effect of eldecalcitol on the
incidence of all fragility fractures caused by osteoporosis,
we conducted post hoc analyses of the phase III clinical
trial to evaluate the incidence of the osteoporotic fractures
defined in the World Health Organization (WHO) Tech-
nical Report, and, also, the incidence of the major osteo-
porotic fractures utilized in the WHO Fracture Risk
Assessment Tool (FRAX), and compared those in the
eldecalcitol group with those in the alfacalcidol group. We
also analyzed the incidence of osteoporotic fractures
stratified by prespecified risk factors for fractures. Elde-
calcitol treatment reduced the incidence of osteoporotic
fractures defined by the WHO more than alfacalcidol
treatment (18.6 % vs. 25.2 %; hazard ratio, 0.70; 95 % CI,
0.54–0.93). Prevalent vertebral fractures, two or more
prevalent vertebral fractures, and total hip BMD T score
less than -2.5 were the risk factors for new osteoporotic
fractures with significant differences between the two
treatments. Eldecalcitol also decreased the incidence of
major osteoporotic fractures in the FRAX more than alfa-
calcidol (11.1 % vs. 16.3 %; hazard ratio, 0.66; 95 % CI,
0.46–0.94). In conclusion, treatment with eldecalcitol
reduced the risk of fragility fractures caused by osteopo-
rosis compared with alfacalcidol administration, which
may result from a potent effect of eldecalcitol on BMD,
bone structure, and bone turnover.
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Introduction
Eldecalcitol is a new active vitamin D3 analogue with a
hydroxypropyloxy group introduced at the 2b position of
1a,25-dihydroxyvitamin D3. Alfacalcidol, 1a-hydrox-
yvitamin D3, is a prodrug of an active form of vitamin
D3. A randomized, double-blind, placebo-controlled,
clinical study demonstrated that, compared to a placebo,
1-year treatment with eldecalcitol significantly increased
lumbar spine and total hip bone mineral density (BMD)
in a dose-dependent manner [1]. Further, in comparison
to alfacalcidol treatment, eldecalcitol treatment signifi-
cantly decreased the incidences of vertebral fractures
(morphometric and clinical) and wrist fractures, with
marked increases in lumbar spine BMD and total hip
BMD, as assessed by a 3-year, randomized, double-
blind, clinical trial [2]. On the basis of these results,
eldecalcitol has been approved for the treatment of
osteoporosis in Japan.
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A characteristic type of fracture frequently found in
osteoporosis is the so-called fragility fracture. However,
diagnosis of fragility fractures in patients with osteoporosis
is often difficult in daily practice because of uncertainty in
evaluating the degree of causative energy loaded onto the
fracture site. Recently, the World Health Organization
(WHO) Scientific Group [3, 4] introduced a new approach
to characterizing fractures relevant to osteoporosis. These
‘‘osteoporotic fractures’’ are fractures whose risk of inci-
dence is associated with low bone mass and whose inci-
dences rise with age after the age of 50 years. Fractures
pertinent to these criteria are those at the spine, distal
forearm (wrist), humerus, ribs, clavicle/scapula/sternum,
pelvis, tibia/fibula, hip, and other femoral fractures. Pre-
vention of these osteoporotic fractures is of prime impor-
tance in patients with osteoporosis. We have already
reported the reduction in the incidence of three major
predefined nonvertebral fractures of the humerus, wrist,
and hip [2]. However, we did not analyze the incidences of
osteoporotic fractures including major fractures used in the
WHO Fracture Risk Assessment Tool (FRAX).
In the present study, we analyzed the data derived from
the phase III clinical trial of the efficacy of eldecalcitol
versus alfacalcidol on fracture prevention in osteoporotic
patients (Clinical Trials Gov Number NCT00144456) to
determine the effect of eldecalcitol on the incidence of
osteoporotic fractures in comparison to that of alfacalcidol.
We also analyzed the effect of each agent on the risk of
major osteoporotic fractures included in FRAX—i.e.,
clinical vertebral fracture and fractures of the hip, distal
forearm, and humerus—without discriminating between
traumatic and nontraumatic fractures. Then, we analyzed
the incidences of osteoporotic fractures stratified by pre-
specified risk factors for fractures at baseline.
Materials and methods
Details of the double-blind fracture prevention clinical
study of eldecalcitol have been published previously [2].
Briefly, 1,054 patients with primary osteoporosis [5, 6]
were divided into two groups: an eldecalcitol group
(n = 528) and an alfacalcidol group (n = 526). They were
given either oral eldecalcitol (0.75 lg) or oral alfacalcidol
(1.0 lg) once a day for 3 years (36 months). Patients with
serum 25-hydroxyvitamin D values lower than 20 ng/ml at
the time of enrollment were given an oral vitamin D3
supplement (400 IU) once a day without calcium supple-
mentation. Patients with lumbar spine or total hip BMD
T score below -1.7 were enrolled if they had one to five
vertebral fractures. Patients without vertebral fractures
were also enrolled if their lumbar spine or total hip BMD
T score was below -2.6 and they were aged 70 years or
older, or if their T score was below -3.4 and they were
aged less than 70 years. Patients with metabolic bone
disease such as primary hyperparathyroidism, Cushing’s
syndrome, premature menopause, poorly controlled dia-
betes mellitus (HbA1c[9 %), or other causes of secondary
osteoporosis or patients who had a history of urolithiasis
were excluded from the study. Patients were also excluded
if they had taken any oral bisphosphonates within 6 months
before entry or for more than 2 weeks during the period
6–12 months before entry, or intravenous bisphosphonates
at any time; had taken glucocorticoids, calcitonin, vitamin
K2, active vitamin D compounds, raloxifene, or hormone
replacement therapy within 2 months; had serum calcium
levels above 10.4 mg/dl or urinary calcium excretion
greater than 0.4 mg/dl GF; or had serum creatinine above
1.3 mg/dl.
The primary endpoint of the study was the incidence of
nontraumatic new vertebral fractures, and the secondary
endpoints were the percent change in lumbar spine BMD
and total hip BMD, percent change of bone turnover
markers, and incidence of nonvertebral fractures. The
incidence of nontraumatic new vertebral fractures was
evaluated by using lateral radiographs of the thoracic and
lumbar spine obtained at baseline and at 6, 12, 24, and
36 months after initiation of drug administration. Inci-
dences of nonvertebral fractures were assessed using
radiographic examinations at the clinical site by investi-
gators, and the data were reported at the time of incidence
to the central facility and analyzed. In this study, we
compared the two treatment groups with respect to the
incidence of osteoporotic fractures as defined by the WHO
Scientific Group [3, 4], their site-specific incidences, and
the incidence of major osteoporotic fractures included in
FRAX. We also analyzed the incidence of osteoporotic
fractures based on prespecified risk factors for fractures at
baseline: age, serum 25-hydroxyvitamin D value, number
and degree of severity of prevalent vertebral fractures,
lumbar spine BMD, and total hip BMD.
Statistical analysis
We performed the analysis for all subjects in the Full
Analysis Set (eldecalcitol group, n = 526; alfacalcidol
group, n = 523). First, the incidences of fractures at any of
the nine osteoporotic fracture sites and their subgroup
analyses were evaluated by Kaplan–Meier estimation.
Then, the incidences of fractures at each respective site
were assessed. The incidences of major osteoporotic frac-
tures were also estimated by the Kaplan–Meier method. To
compare the effects of eldecalcitol with those of alfacal-
cidol, we performed stratified log-rank tests (two-sided,
5 % significance level) and determined the hazard ratios
and the 95 % confidence intervals of those incidences by
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stratified Cox regression models, as described in the sub-
group analyses of the previous report [2], with adjustment
for the number of prevalent vertebral fractures at baseline
(categories were no fracture, one fracture, or more than one
fracture).
Results
There were no significant differences in the patients’
background data with regard to age, percentage of male
patients, body mass index, the prevalence of vertebral
fractures, nonvertebral fractures, BMD, or metabolic bone
markers (Table 1).
The incidence of all osteoporotic fractures for 3 years
was 18.6 % in the eldecalcitol group and 25.2 % in the
alfacalcidol group, according to the Kaplan–Meier estimate
(Fig. 1a), and the risk of osteoporotic fracture in the el-
decalcitol group was significantly lower than in the alfa-
calcidol group (hazard ratio, 0.70; 95 % CI, 0.54–0.93;
p = 0.013). The incidence of nonvertebral osteoporotic
fractures was 5.8 % in the eldecalcitol group and 9.7 % in
the alfacalcidol group (Fig. 1b), indicating a significant
decrease in the risk in the eldecalcitol group relative to that
in the alfacalcidol group (hazard ratio, 0.59; 95 % CI,
0.37–0.94, p = 0.026).
The incidence of the four major osteoporotic clinical
fractures used in FRAX (clinical vertebral fractures, and
fractures of the humerus, distal forearm, and hip) for
3 years was 11.1 % in the eldecalcitol group and 16.3 % in
the alfacalcidol group. The risk of these fractures was
significantly lower in the eldecalcitol group than in the
alfacalcidol group (hazard ratio, 0.66; 95 % CI, 0.46–0.94;
p = 0.020) (Fig. 2).
In the subgroup analyses of osteoporotic fractures, all
the values of the point estimates for hazard ratio in the
eldecalcitol group were less than 1.0 compared to the
alfacalcidol group. The categories of subgroups that
showed marked significant differences (p \ 0.01) were
presence of prevalent vertebral fractures (hazard ratio,
0.66; 95 % CI, 0.49–0.89; p = 0.007), two or more pre-
valent vertebral fractures (hazard ratio, 0.59; 95 % CI,
0.41–0.86; p = 0.006), and total hip BMD T-score of less
than -2.5 (hazard ratio, 0.55; 95 % CI, 0.36–0.84;
p = 0.006) (Fig. 3).
Site-specific numbers of osteoporotic fractures of the
vertebrae, ribs, clavicle/scapula/sternum, tibia/fibula,
and distal forearm that occurred during the 3-year trial
were smaller in the eldecalcitol group than in the
alfacalcidol group, but a statistically significant differ-
ence was observed only for vertebra and distal forearm
(vertebra: hazard ratio, 0.72; 95 % CI, 0.52–0.99; distal
forearm: hazard ratio, 0.28; 95 % CI, 0.11–0.69)
(Table 2).
Discussion
This study clearly demonstrated that, compared with
1.0 lg daily alfacalcidol administration, daily adminis-
tration of 0.75 lg eldecalcitol reduced the risk of osteo-
porotic fractures as defined by WHO and decreased the
risk of major osteoporotic fractures included in FRAX. A
significant decrease in the incidence of nonvertebral
osteoporotic fractures was also observed in the eldecalc-
itol group.
In the subgroup analysis, eldecalcitol was found to be
more effective at reducing the risk of osteoporotic fractures
than alfacalcidol in patients with total hip BMD T score
less than -2.5. The hazard ratio for patients with two or
more prevalent vertebral fractures was markedly smaller
than the hazard ratios for patients with one or no prevalent
vertebral fracture. Thus, eldecalcitol seems to be more
effective than alfacalcidol in preventing osteoporotic
fractures in patients with multiple prevalent vertebral
fractures.





Age (years) 72.2 ± 6.59 72.1 ± 6.62
Male patients [n (%)] 9 (1.71) 15 (2.87)
Body mass index (kg/m2) 22.3 ± 3.19 22.3 ± 3.20
Number of prevalent vertebral
fractures
1.19 ± 1.28 1.25 ± 1.36
0 [n (%)] 198 (37.6) 193 (36.9)
1 [n (%)] 155 (29.5) 159 (30.4)
C2 [n (%)] 173 (32.9) 171 (32.7)
Prevalent vertebral fracture
Grade 0 [n (%)] 198 (37.6) 193 (36.9)
Grade 1 [n (%)] 110 (20.9) 118 (22.6)
Grade 2 [n (%)] 132 (25.1) 102 (19.5)
Grade 3 [n (%)] 86 (16.3) 110 (21.0)
History of nonvertebral fracture
Absent [n (%)] 367 (69.8) 379 (72.5)
Present [n (%)] 159 (30.2) 144 (27.5)
Lumbar spine bone mineral
density (BMD) T score
-2.70 ± 0.94 -2.72 ± 0.90
Total hip BMD T score -2.26 ± 0.82 -2.27 ± 0.79
Bone alkaline phosphatase
(BAP) (U/l)
33.4 ± 14.4 33.8 ± 12.5
Urinary NTx (nmol BCE/mmol Cr) 58.0 ± 58.7 57.0 ± 32.7
Data are mean ± SD. There were no significant differences in the
patients’ background data
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In the previous study, we demonstrated the efficacy of
eldecalcitol in preventing morphometric vertebral fractures
and nonvertebral fragility fractures at three major sites
(humerus, wrist, and hip) [2]. In this study, we analyzed the
incidences of all radiographically confirmed osteoporotic
fractures of the vertebrae, ribs, pelvis, humerus, clavicle/
scapula/sternum, hip, other femoral sites, tibia/fibula, and
distal forearm. Then, we compared the incidences of the
nonvertebral osteoporotic fractures. We also calculated the
incidences of the four major osteoporotic fractures listed in
the FRAX [vertebrae (clinical fracture), hip, distal forearm,
and humerus]. These data compatibly indicated the supe-
rior efficacy of eldecalcitol compared to that of alfacalcidol
on the prevention of fractures in patients with osteoporosis.
The superiority of eldecalcitol in preventing nonvertebral
osteoporotic fractures appeared to be largely the result of
reductions in the incidence of fractures of the ribs, clavicle/
scapula/sternum, tibia/fibula, and distal forearm.
The effect of eldecalcitol on reducing the risk of oste-
































































Hazard ratio, 0.59 (95%CI, 0.37-0.94)
P = 0.026
AlfacalcidolEldecalcitol
Fig. 1 Kaplan–Meier estimates
of the incidence of all
osteoporotic fractures defined
by the WHO Scientific Group
(a), and the incidence of
nonvertebral osteoporotic
































Fig. 2 Kaplan–Meier estimates
of the incidence of major
osteoporotic fractures included
in the Fracture Risk Assessment
Tool (FRAX) in the eldecalcitol
and alfacalcidol groups
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seems to depend on the potent effect of eldecalcitol in
increasing BMD and strengthening bone structure. Elde-
calcitol was shown to increase lumbar BMD by 3.3 % and
total hip BMD by 1.5 % in 1 year in comparison to placebo
[1] and to increase lumbar BMD by 3.3 % and total hip
BMD by 2.7 % in 3 years compared to alfacalcidol [2].
Subgroup analysis in this study confirmed the potent effi-
cacy of eldecalcitol compared to alfacalcidol. With elde-
calcitol treatment, urinary NTx, a bone resorption marker,
was observed to decrease by 20 % in 3 months in com-
parison to baseline levels [1] and by 23 % in 3 years
compared to that when treated with alfacalcidol [2]. Also,
femoral bone geometry assessment using clinical computed
tomography (multidetector-row CT) scanning has shown
that, compared with alfacalcidol, eldecalcitol more mark-
edly increases the cross-sectional cortical bone area in
patients with osteoporosis, maintains the thickness of cor-
tical bone, and improves the bone biomechanical parame-
ters of the femoral neck [7]. The volumetric BMD value at
the femoral neck also significantly increased with elde-
calcitol treatment compared to with alfacalcidol treatment.
These data strongly suggest that eldecalcitol improves the
Favors Eldecalcitol Favors Alfacalcidol
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Fig. 3 Subgroup analyses of the effect of eldecalcitol in comparison with alfacalcidol on osteoporotic fractures
Table 2 Osteoporotic fractures
defined by the WHO Scientific
Group and their site-specific
incidences
a Tibial and fibular fractures







All osteoporotic fractures 90 119 0.70 (0.54–0.93)
Nonvertebral osteoporotic fractures 28 46 0.59 (0.37–0.94)
Osteoporotic fractures at specific sites
Vertebra 64 83 0.72 (0.52–0.99)
Ribs 8 14 0.56 (0.23–1.33)
Pelvis 3 1 2.95 (0.31–28.34)
Humerus 2 1 1.92 (0.17–21.22)
Clavicle, scapula, sternum 1 3 0.33 (0.03–3.20)
Hip 7 5 1.41 (0.45–4.44)
Other femoral fracture 0 1 –
Tibia, fibulaa 1 5 0.20 (0.02–1.69)
Distal forearm 6 21 0.28 (0.11–0.69)
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material strength of bone and also the cortical bone
structure.
Preventing a chain reaction of fragility fractures in
patients with osteoporosis is critically important in daily
clinical practice. Meta-analysis studies suggest that a pre-
vious fracture history is associated with a significant
(approximately doubled) increase in risk of any fracture
compared with individuals without a prior fracture [8, 9].
Robinson et al. [10] reported that fractures of the hip, wrist,
and proximal part of humerus were associated with a high
risk of later re-fracture at any of the four sites they exam-
ined (hip, wrist, proximal part of the humerus, and ankle),
and the relative risks were 5.76, 3.98, and 4.87, respec-
tively. Center et al. [11] reported that absolute risk of sub-
sequent fracture was increased in women across all age
groups for most fracture types with clinical symptoms,
including hip, vertebra, upper limb, ribs, and lower limb,
and their relative risks were 2.79, 2.52, 1.69, 1.84, and 1.39,
respectively. These data indicate that a prevalent fracture is
a strong indicator of secondary fractures. This study con-
firmed the potent efficacy of eldecalcitol in preventing
subsequent osteoporotic fractures in patients with prevalent,
especially multiply prevalent, vertebral fractures.
This study has several limitations. First, this was a post
hoc analysis. Second, this study had no placebo group.
Third, the study population was not large enough to reli-
ably evaluate the subgroup analyses and analyses of site-
specific osteoporotic fractures. Therefore, these analyses
should be considered exploratory.
In conclusion, daily administration of 0.75 lg elde-
calcitol reduces the risk of osteoporotic fractures compared
with 1.0 lg alfacalcidol administration in 3 years. Elde-
calcitol was also superior to alfacalcidol in reducing non-
vertebral osteoporotic fractures, which could be the result
of the potent effect that eldecalcitol has on BMD, bone
structure, and bone turnover.
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